Abstract:Background: As one of the most common causes of death in advanced non-small cell lung cancer (NSCLC), brain metastases (BM) have attracted attention and debate about treatment options, especially for patients with negative driver genes or resistance to targeted agents.Therefore, we conducted a meta-analysis to investigate the potential benefit of different therapeutic regimens for intracranial lesions in non-targeted therapy NSCLC patients.Methods: A comprehensive search was conducted in databases including PubMed, Embase, and the Cochrane Library.The primary endpoints included the intracerebral objective response rate (icORR) and intracerebral progression-free survival (iPFS) in patients with BM.Results: Thirty-six studies involving 1,774 NSCLC patients with baseline BM were included in this metaanalysis.Antitumor agents plus radiotherapy (RT) showed the most significant synergistic effects; the highest pooled icORR that appeared in the combination of immune checkpoint inhibitor (ICI) and RT was 81% [95% confidence interval (CI): 16-100%], and the median iPFS was 7.04 months (95% CI: 2.54-11.55months).The pooled icORR and median iPFS of RT plus chemotherapy were 46% (95% CI: 34-57%) and 5.7 months (95% CI: 3.90-7.50months), respectively.The highest median iPFS in nivolumab plus ipilimumab plus chemotherapy was 13.5 months (95% CI: 8.35-18.65 months).ICI plus chemotherapy also showed potent antitumor activity in BM, with a pooled icORR of 56% (95% CI: 29-82%) and a median iPFS of 6.9 months (95% CI: 3.20-10.60months).Notably, the subgroup analysis indicated that the pooled icORR of patients in programmed cell death-ligand 1 (PD-L1) (≥50%) who received ICI was 54% (95% CI: 30-77%), and that of patients who received first-line ICI was 69.0% (95% CI: 51-85%).Conclusions: ICI-based combination treatment provides a long-term survival benefit for non-targeted therapy patients, with the most significant benefits observed in improving icORR and prolonging overall survival (OS) and iPFS.In particular, patients who received first-line treatment or who were PD-L1-positive had a more significant survival benefit from aggressive ICI-based therapies.For patients with a PD-L1negative status, chemotherapy plus RT led to better clinical outcomes than other treatment regimens.These innovative findings could help clinicians to better select therapeutic strategies for NSCLC patients with BM.

Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases

Research Progress of Targeted Therapy in Non-small Cell Lung Cancer Brain Metastases

Molecular subtyping of brain metastases and implications for therapy

Treatment options for brain metastases in patients with non-small cell lung cancer

Advanced treatment strategies for NSCLC brain metastasis in the new drug era

Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape

Treatment of brain metastases from non-small cell lung cancer: preclinical, clinical, and translational research

Managing Central Nervous System Spread of Lung Cancer: The State of the Art

Current pharmacologic treatment of brain metastasis in non-small cell lung cancer

Lung Cancer with Brain Metastasis—Treatment Strategies and Molecular Characteristics

Treatment and Prevention of Brain Metastases in Small Cell Lung Cancer

Efficacy of Different Therapies for Brain Metastases of Non-Small Cell Lung Cancer: a Systematic Review and Meta-Analysis

Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis

Therapeutic strategies and relevant clinical problems in non-small cell lung cancer with brain metastases

Therapy for Non-Small-cell Lung Cancer Patients with Brain Metastasis

A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases

Treatment Modes for EGFR Mutations in Patients with Brain Metastases from Non-Small Cell Lung Cancer: Controversy, Causes, and Solutions

Immune Checkpoint Inhibitors in the Management of Brain Metastases from Non-Small Cell Lung Cancer: A Comprehensive Review of Current Trials, Guidelines and Future Directions

Modern Radiation Therapy for the Management of Brain Metastases From Non-Small Cell Lung Cancer: Current Approaches and Future Directions

Treatment and survival of patients with small cell lung cancer and brain metastasis

Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis